Maverick Capital’s Pacira BioSciences PCRX Stock Holding History

Maverick Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,823	Closed	-$233K	–	448
2023 Q2	$233K	Buy	+5,823	New	+$241K	0.01%	380
2021 Q3	–	Sell	-1,108	Closed	-$67K	–	761
2021 Q2	$67K	Buy	+1,108	New	+$70.1K	﹤0.01%	589
2020 Q2	–	Sell	-48,159	Closed	-$1.61M	–	648
2020 Q1	$1.61M	Sell	48,159 -53,060	-52%	-$2.2M	0.03%	217
2019 Q4	$4.58M	Sell	101,219 -71,161	-41%	-$3.02M	0.07%	144
2019 Q3	$6.56M	Buy	+172,380	New	+$6.88M	0.1%	88
2016 Q2	–	Sell	-1,610,932	Closed	-$85.3M	–	147
2016 Q1	$85.3M	Buy	+1,610,932	New	+$94.2M	1.35%	27

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Maverick Capital's PCRX Position: Q3 2023 in Review

Maverick Capital sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 5,823 shares — an estimated $233K sold.

Maverick Capital first reported a position in PCRX in Q1 2016 and held it in 6 quarters. The position peaked at $85.3M in Q1 2016. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

Maverick Capital reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
Maverick Capital sold 5,823 Pacira BioSciences shares in Q3 2023, an estimated $233K.
Maverick Capital first reported a position in Pacira BioSciences in Q1 2016 and held it in 6 quarters.
Maverick Capital's Pacira BioSciences position peaked at $85.3M in Q1 2016.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Maverick Capital's 13F filing for Q3 2023, filed 14 Nov 2023.